[Federal Register: March 10, 2006 (Volume 71, Number 47)] [Notices] [Page 12364-12365] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr10mr06-78] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Pediatric Advisory Committee; Amendment of Notice AGENCY: Food and Drug Administration. ACTION: Notice. ----------------------------------------------------------------------- [[Page 12365]] The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pediatric Advisory Committee. This meeting was announced in the Federal Register of February 1, 2006 (71 FR 5343). The amendment is being made to reflect a change in the Date and Time and Agenda portions of the document. The starting time of the meeting has been moved to 7:30 a.m. and the committee will now also hear and discuss information on cardiovascular adverse events possibly related to ADHD medications. There are no other changes. FOR FURTHER INFORMATION CONTACT: Jan N. Johannessen, Office of Science and Health Coordination (HF-33), Food and Drug Administration, 5600 Fishers Lane (for express delivery, rm. 14C-06), Rockville, MD 20857, 301-827-6687, e-mail: Jan.Johannessen@fda.hhs.gov, or the FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 8732310001. Please call the Information Line for up-to-date information on this meeting. SUPPLEMENTARY INFORMATION: In the Federal Register of February 1, 2006, FDA announced that a meeting of the Pediatric Advisory Committee would be held on March 22, 2006, from 8 a.m. to 6 p.m., and that the committee would receive an update on efforts to better understand cardiovascular adverse events possibly related to ADHD medications. On page 5343, in the first column, the Date and Time portion of the document is amended to read as follows: Date and Time: The meeting will be held on March 22, 2006, from 7:30 a.m. to 6 p.m. On page 5343, in the second column, the Agenda portion of the document is amended to read as follows: Agenda: The Pediatric Advisory Committee will hear and discuss a report by the agency, as mandated in Section 17 of the Best Pharmaceuticals for Children Act (BPCA), on adverse event reports possibly related to clofarabine (CLOLAR), irbesartan (AVAPRO), sibutramine (MERIDIA), and the mixed salts amphetamine product (ADDERALL). In continuation of a prior committee discussion of adverse events for the class of methylphenidate products used to treat attention deficit hyperactivity disorder (ADHD), the committee will hear and discuss neuropsychiatric adverse events possibly related to other approved ADHD medications. The presentations will focus on neuropsychiatric adverse event reports and clinical trial data from approved ADHD medications. The committee will also hear and discuss information on cardiovascular adverse events possibly related to ADHD medications. The background material will become available no later than the day before the meeting and will be posted under the Pediatric Advisory Committee Docket site at http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/ohrms/dockets/ac/acmenu.htm. (Click on the year 2006 and scroll down to Pediatric Advisory Committee meetings.) This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees. Dated: March 3, 2006. Jason Brodsky, Acting Associate Commissioner for External Relations. [FR Doc. E6-3435 Filed 3-9-06; 8:45 am] BILLING CODE 4160-01-S